SLC5A2 and hydrops fetalis: Results from recent CV and renal outcome trials are very promising highlighting SGLT2-inhibitors' potential to treat T2DM, CV disease, HF and CKD—conditions that are invariably linked by the common CV risk factor profile [18, 22, 23, 52].